«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

29卷

期数:

2023年05期

页码:

526-531

栏目:

临床医学

出版日期:

2023-09-20

文章信息/Info

Title:

Efficacy of Conbercept in the treatment of wet age-related macular degeneration in the real world

文章编号:

1006-8147（2023）05-0526-06

作者:

郭娟¹; 2; 任新军¹; 李筱荣¹

（1.天津医科大学眼科医院，眼视光学院，眼科研究所，国家眼耳鼻喉疾病临床医学研究中心天津市分中心，天津市视网膜功能与疾病重点实验室，天津300384；2.天津大学爱尔眼科医院眼底病科，天津 300190）

Author(s):

GUO Juan¹; ²; REN Xin-jun¹; LI Xiao-rong¹

（1.Tianjin Medical University Eye Hospital，Eye Institute and Shool of Optometry，Tianjin Branch of National Clinical Research Center for Ocular Disease， Tianjin key laboratory of Retinal Functions and Diseases，Tianjin 300384，China；2. Department of Fundus disease，Aier Eye Hospital，Tianjin University，Tianjin 300190，China）

关键词:

康柏西普; 玻璃体腔内注射; 年龄相关性黄斑变性; 真实世界

Keywords:

Conbercept; intravitreal injection; age-related macular degeneration; real-world

分类号:

R774.5

DOI:

-

文献标志码:

A

摘要:

目的：研究真实世界下玻璃体腔内注射康柏西普治疗湿性年龄相关性黄斑变性（wAMD）的临床疗效。方法：回顾性分析2017年11月—2020年10月在天津大学爱尔眼科医院接受康柏西普注射液治疗湿性年龄相关性黄斑变性的92例患者（102眼），采用治疗前后自身对照，回顾性病例分析法研究在真实世界下的临床资料，主要评价指标为患眼1年内的注射次数、第1次治疗前与第1次治疗后1、3、6个月及1年的最佳矫正视力（BCVA）、中央视网膜厚度（CRT）、每位患者第1次注射前后的短期眼压的变化及不良反应。结果：患者年龄为53～88岁[平均（68.92±9.61）岁]，单眼平均注射次数为（4.06±0.94）次；治疗后1、3、6个月及1年BCVA、CRT呈逐渐减低并趋于平稳，与治疗前比较差异有统计学意义（均P<0.01），患者治疗后3、6个月及1年时的BCVA、CRT与治疗后1个月比较差异有统计学意义（均P<0.05）。患者第1次注药术后即刻、术后30 min、术后1 h眼压与术前相比差异有统计学意义（均P<0.01），术后30 min、术后1 h、术后2 h、术后第2天眼压与术后即刻相比差异有统计学意义（均P<0.01）。术后5例出现结膜下出血于2周左右自行吸收，6例患者眼压高于21 mmHg（1 mmHg=0.133 kPa）于3 d复查时降至正常，其余均未发生其他严重不良反应。结论：在真实世界下康柏西普治疗wAMD能明显改善视力，消除黄斑区CNV，早期治疗效果尤为明显，且玻璃体腔注射康柏西普后短时间内眼压轻度升高，但是波动并不明显。

Abstract:

Objective： To study the clinical efficacy of intravitreal injection of Conbercept in the treatment of wet age-related macular degeneration （wAMD） in the real world. Methods：A retrospective analysis was performed on 92 patients （102 eyes） with wet age-related macular degeneration who received Conbercept injection in Aier Eye Hospital of Tianjin University from November 2017 to October 2020. Self-control before and after treatment was used. Clinical data in the real world were studied by retrospective case analysis. The best corrected visual acuity（BCVA），central retinal thickness（CRT），short-term intraocular pressure changes and adverse reactions before and after the first injection in each patient were measured at 1，3，6 months and 1 year after the first treatment. Results：A total of 102 eyes aged 53-88 years[mean(68.92±9.61)years]，the average number of injections in one eye was（4.06±0.94）. BCVA and CRT values gradually decreased and stabilized at 1，3，6 months and 1 year after treatment，which were significantly different from those before treatment（all P<0.01）. The BCVA and CRT of patients at 3，6 months and 1 year after the first treatment was significantly different from that at 1 month after treatment （all P<0.05）. The intraocular pressure immediately after the first infusion，30 min after surgery，and 1 h after surgery were significantly different from those before surgery（all P<0.01），there were statistically significant differences in postoperative intraoperative pressure 30 min，1 h，2 h and 2nd day compared with immediate postoperative pressure（all P<0.01）. Subconjunctival hemorrhage occurred in 5 patients and was absorbed by itself about 2 weeks after surgery；intraocular pressure in 6 patients was higher than 21 mmHg（1 mmHg=0.133 kPa） and decreased to normal at the re-examination 3 days later；while no other serious adverse reactions occurred in the rest. Conclusion：In the real world，the treatment of wAMD with Conbercept can significantly improve visual acuity and eliminate CNV in macular area. The effect of early treatment is particularly obvious，and after intravitreal injection of Conbercept slightly increased in a short time，but the fluctuation of intraocular pressure is not obvious.

参考文献/References:

[1] 丁小燕，王志容，孙立梅. 创造向未来：湿性AMD治疗进展及展望[J].中华实验眼科杂志，2019，37（1）：63-68.
[2] PENGFEI J，HANYU T，QINGHUA P. Ranibizumab and conbercept for treating wet age-related macular degeneration in China：a systematic review and meta-analysis[J]. Medicine，2021，100（48）：e27774.
[3] PUGAZHENDHI A，HUBBELL M，JAIRAM P，et al. Neovascular macular degeneration：a review of etiology，risk factors，and recent advances in research and therapy[J]. Int J Mol Sci，2021，22（3）：1170.
[4] CHAPMAN N A，JACOBS R J，BRAAKHUIS A J. Role of diet and food intake in age-related macular degeneration：a systematic review[J]. Clin Exp Ophthalmol，2019，47（1）：106-127.
[5] WONG W L，SU X，LI X，et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040：a systematic review and meta-analysis[J]. Lancet Glob Health，2014，2（2）：106-116.
[6] CABRAL DE GUIMARAES T A，DAICH VARELA M，GEORGIOU M，et al. Treatments for dry age-related macular degeneration：therapeutic avenues，clinical trials and future directions[J].Br J Ophthalmol，2022，106（3）：297-304.
[7] MEHTA H，TUFAIL A，DAIEN V，et al. Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors[J]. Prog Retin Eye Res，2018，65：127-146
[8] 陈晓冬，陆慧琴，王彤. 康柏西普在眼部新生血管性疾病中的应用进展[J]. 国际眼科杂志，2022，22（8）：1361-1364.
[9] SANTARELLI M，DIPLOTTI L，SAMASSA F，et al.Advances in pharmacotherapy for wet agerelated macular degeneration[J]. Expert Opin Pharmacother，2015，16（12）：1769-1781
[10] KATAJA M，HUJANEN P，HUHTALA H，et al.Outcome of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration in real-life setting[J].Br J Ophthalmol，2018，102（7）：959-965.
[11] LU X，SUN X. Profile of conbercept in the treatment of neovascular age-related macular degeneration[J]. Drug Des Devel Ther，2015，9：2311-2320.
[12] WANG Q，LI T，WU Z，et al. Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo[J]. PLoS One，2013，8（8）：e70544.
[13] 高新晓，马子程，严然，等. 玻璃体腔内注射康柏西普治疗湿性年龄相关性黄斑变性的真实世界结果[J]. 中国医药，2020，15（5）：783-786.
[14] GARWEG J G，GERHARDT C，KODJIKIAN L，et al. Real-life experience with aflibercept and ranibizumab in the treatment of newly diagnosed neovascular age-related macular degeneration over 24 months[J].J Ocul Pharmacol Ther，2017，33（7）：567-572.
[15] 张司，李青，陈晖. 康柏西普治疗湿性年龄相关性黄斑变性患者应答反应的临床观察[J]. 国际眼科杂志，2020，20（5）：787-790.
[16] SPILSBURY K，GARRETT K L，SHEN W Y，et al. Overexpression of vascular endothelial growth factor（VEGF） in the retinal pigment epithelium leads to the development of choroidal neovascularization[J].Am J Pathol，2000，157（1）：135-144.
[17] ISHIBASHI T，HATA Y，YOSHIKAWA H，et al. Expression of vascular endothelial growth factor in experimental choroidal neovascularization[J]. Graefes Arch Clin Exp Ophthalmol，1997，235（3）：159-167.
[18] YU D C，LEE J S，YOO J Y，et al. Soluble vascular endothelial growth factor decoy receptor FP3 exerts potent antiangiogenic effects[J].Mol Ther，2012，20（5）：938-947.
[19] LI H，LEI N，ZHANG M，et al. Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit[J]. Exp Eye Res，2012，97（1）：154-159.
[20] ZHANG M，ZHANG J，YAN M，et al. KH902 Phase 1 study group. A phase 1 study of KH902，a vascular endothelial growth factor receptor decoy，for exudative age-related macular degeneration[J]. Ophthalmology，2011，118（4）：672-678.
[21] LI X，XU G，WANG Y，et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration：results from a 12-month randomized phase 2 study：AURORA study[J]. Ophthalmology，2014，121（9）：1740-1747.
[22] LIU K，SONG Y，XU G，et al. Conbercept for treatment of neovascular age-related macular degeneration：results of the randomized phase 3 PHOENIX study[J]. Am J Ophthalmol，2019，197：156-167.
[23] WILLIAMSON T R，BARRETT G V. Feasibility of measuring eye movements in real-world and simulated driving situations[J]. Percept Mot Skills，1966，23（1）：329-330.
[24] CHEUNG CMG，LAI TYY，TEO K，et al. Polypoidal choroidal vasculopathy：consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the Asia-Pacific ocular imaging society PCV workgroup[J]. Ophthalmology，2021，128（3）：443-452.
[25] SPAIDE R F，JAFFE G J，SARRAF D，et al. Consensus nomenclature forreporting neovascular age-related macular degeneration data：consensus on neovascular age-related macular degeneration nomenclature study group[J]. Ophthalmology，2020，127（5）：616-636.
[26] THOONGSUWAN S，HANUTSAHA P，CHANTARASORN Y，et al. Treatment outcome of wet age-related macular degeneration management in thailand：a retrospective real-world study（TOWER study）[J].Ophthalmol Ther，2022，11（2）：739-757.
[27] PAPADOPOULOS N，MARTIN J，RUAN Q，et al. Binding and neutralization of vascular endothelial growth factor（VEGF） and related ligands by VEGF Trap，ranibizumab and bevacizumab[J]. Angiogenesis，2012，15（2）：171-185.
[28] 张香闺，宋艳萍，黄珍，等. 康柏西普治疗新生血管性老年性黄斑变性中1型黄斑新生血管合并不同类型视网膜色素上皮脱离的疗效观察[J].中华眼底病杂志，2022，38（3）：217-224.
[29] 万承，林仲，林克，等.不同药物玻璃体内注射后短期眼压变化[J].中华眼外伤职业眼病杂志，2022，44（7）：486-491.
[30] SUDHALKAR A，BILGIC A，VASAVADA S，et al. Current intravitreal therapy and ocular hypertension：a review[J].Indian J Ophthalmol，2021，69（2）：236-243.
[31] 韩嵩.玻璃体内注射雷珠单抗治疗新生血管性年龄相关性黄斑变性的疗效及对患者血清CRP VEGF眼压和视力的影响[J].河北医学，2020，26（9）：1478-1482.
[32] HOGUET A，CHEN P P，JUNK A K，et al. The effect of anti-vascular endothelial growth factor agents on intraocular pressure and glaucoma：a report by the American Academy of Ophthalmology[J]. Ophthalmology，2019，126（4）：611-622.
[33] TANWAR S，SHARMA A K，SRIVASTAVA R M，et al.Comparison between two intravitreal injection techniques with respect to fluid reflux，intraocular pressure，and therapeutic effect[J].Oman J Ophthalmol，2021，14（1）：33-37.
[34] BILGIC A，KODJIKIAN L，CHHABLANI J，et al.Sustained intraocular pressure rise after the treat and extend regimen at 3 years：aflibercept versus ranibizumab[J]. Ophthalmol，2020，2020：7462098.

相似文献/References:

备注/Memo

备注/Memo:

基金项目 天津市医学重点学科（专科）建设项目资助（TJYXZDXK-037A）
作者简介 郭娟（1987-），女，主治医师，硕士在读，研究方向：眼科学；通信作者：李筱荣，E-mail：xiaorli@163.com。

常用功能

更新日期/Last Update: 2023-09-25